[
    [
        {
            "time": "",
            "original_text": "医药生物行业: 国家级辅助用药目录将出台, 医保转移利好刚性用药企业",
            "features": {
                "keywords": [
                    "医药生物",
                    "国家级辅助用药目录",
                    "医保转移",
                    "刚性用药企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业: 国家级辅助用药目录将出台, 医保转移利好刚性用药企业",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报: 政策多发扰动期, 建议关注品牌中药的配置价值",
            "features": {
                "keywords": [
                    "医药生物",
                    "政策多发",
                    "扰动期",
                    "品牌中药",
                    "配置价值"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报: 政策多发扰动期, 建议关注品牌中药的配置价值",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业2019年度投资策略报告: 继续看好创新药企及细分领域龙头企业的發展",
            "features": {
                "keywords": [
                    "医药行业",
                    "2019年度",
                    "投资策略",
                    "创新药企",
                    "细分领域龙头企业"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业2019年度投资策略报告: 继续看好创新药企及细分领域龙头企业的發展",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]